Croda International (CRDAN) AI Stock Analysis

Croda International

(BMV:CRDAN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Differentiated specialty chemicals modelCroda’s value-added products are embedded in customer formulations and improve performance, stability, delivery or efficacy. This supports premium positioning, repeat B2B demand and customer switching costs, creating a durable foundation for margins and relationships across several end markets.

Negative Factors

Post-2022 earnings normalizationThe sharp normalization after exceptional 2022 performance shows that Croda’s earnings trajectory remains uneven. Modest recent revenue recovery and lower profitability make sustained earnings compounding less certain, particularly if end-market demand does not broaden.

Croda International Business Overview & Revenue Model

Company Description

Croda International Plc, established in 1925 and headquartered in Goole, United Kingdom, is a global leader in the development, manufacture, and supply of high-performance specialty chemicals. The company serves a diverse international client base ac...

Croda International Earnings Call Summary

Earnings Call Date:Jul 27, 2026(Q2-2026)|Next Earnings Date:Feb 22, 2027

Earnings Call SentimentPositive

The call presented a broadly positive operational and financial picture: organic growth, margin expansion, improved EPS and cash flow, strong outperformance in Consumer Care (notably Beauty Actives) and progress on transformation and AI initiatives. Headwinds remain in certain areas — Pharma Solutions phasing and lumpiness, Crop Protection weakness, regional F&F disruption, working-capital outflow and input-cost volatility — but management reiterated FY guidance and a clear path to their 3-year targets, viewing many challenges as within management control.

Positive Updates

Revenue and Sales Growth

Group sales up 5% in constant currency to GBP 881m in H1; volumes +1% and price/mix +4%; organic sales guidance reiterated at 3–6% for FY2026.

Negative Updates

Pharma Solutions Underperformance and Lumpiness

Pharma Solutions (under 30% of pharma sales, c. GBP 60m) was below expectations in H1 due to phasing and lumpy project timing; management expects project revenues to improve in H2 but visibility remains more variable.

Company Guidance

Management reiterated full‑year 2026 guidance: organic sales growth of 3–6% and a further increase in adjusted operating margin, with adjusted operating profit expectations unchanged, and said the group remains on track to deliver its 2028 financial framework. In H1 the business delivered sales +5% to £881m (new & protected products +7%), volumes +1%, price/mix +4%; adjusted operating profit +7% to £156m, EBITDA £208m, EPS +9% to 78p, free cash flow £38m (vs £28m), net debt £578m and leverage ~1.4x. Margins expanded 50bps to 17.7% aided by £18m of transformation savings in H1 (cumulative £46m) against a £100m transformation target; management expects operating margins to increase sequentially in H2, Pharma Solutions project revenues to recover in H2, working capital (H1 outflow £68m) to improve as a programme delivers ~£50m structural savings by 2028 (offsetting a £20–30m p.a. growth drag), and H1 capex was £43m.

Croda International Peers Comparison

Overall Rating

Financial Indicators

MX:CRDAN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%

* Basic Materials Sector Average

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Croda International AI Stock Analysis